Orcipol (Ciprofloxacin & Ornidazole)
COMPOSITION
Each film coated tablet contains ciprofloxacin
hydrochloride equivalent to 500 mg of ciprofloxacin and 500 mg of ornidazole.
THERAPEUTIC INDICATIONS
Orcipol is indicated for treatment of the
following infections caused by strains sensitive to the combination of
ciprofloxacin and ornidazole:
- Infectious and inflammatory diseases of pelvic minor organs including post-
operative and post-abortion prophylaxis;
- Infections of urogenital system: chronic and acute pyelonephritis, cystitis,
urethritis, prostatitis, epididymitis, including complicated and recurrent;
- Sexually transmitted infections: chlamidiosis, mycoplasmosis, gonorrhea,
trichomoniasis, mixed infections;
- Infections of respiratory tracts – acute bronchitis, chronic bronchitis
exacerbation, pneumonia, infected bronchiectasis, lung abscess, pleural empyema;
- Infections of ENT organs: sinusitis, external otitis and otitis media,
mastoiditis.
- Skin, soft tissues, joint and bone infections.
- Infections of abdominal cavity: diarrhea, caused by bacterial or protozoal
microorganisms.
CONTRAINDICATIONS
- Hypersensitivity to ciprofloxacin or
ornidazole.
- Pregnancy and lactation;
- Infancy and adolescence younger 15 years.
- Central nerve system diseases, acute neurological diseases.
ADVERSE EFFECTS
Nausea, vomiting, diarrhea, abdominal pains,
headaches, vertigo, sleep disturbances, cosinophilia, leucopenia, granulopenia,
change of thrombocyte numbers, allergic reactions may be reported. Seldom
photosensitization.
PRECAUTIONS
The dosage adjustment is required for patients
with renal dysfunction. Orcipol is cautiously administered in elder patients, in
case of cerebral atherosclerosis, cerebral circulation disorder, epilepsy, and
spastic syndrome of unknown etiology.
DRUG INTERACTIONS
Theophylline: the co-administration of
ciprofloxacin with theophylline results in increasing of theophylline plasma
concentrations, owing to competitive inhibition in binding site of cytochrome
P450, results in increasing of theophylline half-time and increasing of toxic
action, associated with theophylline.
Anticoagulants: ornidazole potentiates indirect anticoagulants effect and
increases the duration of vecuronium bromide effect.
Warfarin: the co-administration of ciprofloxacin with warfarin increases the
risk of bleeding.
The co-administration with antacids and drugs containing ions of Al, Zn, Fe and
Mg; may cause decreasing of ciprofloxacin absorption that is why the dosage
interval between these drugs should be not less than 4 hours.
DOSAGE AND ADMINISTRATION
1 tablet of Orcipol should be orally administered
2 times/daily.
Tablets should be administered without chewing and with the sufficient quantity
of liquid. Orcipol may be used before meal or 2 hours after it.
MANUFACTURED FORM
Box containing 10 film coated tablets.
|
|
Alimentary Tract and Metabolism
All Products
Bactamed
Cefamed
Clavomed Suspension
Clavomed Tablet
Doramycin
Fluzamed
Levoximed Infusion
Levoximed Tablet
Lynozid
Merkacin
Orcipol
Ziromin
|